ClinicalTrials.gg
CompletedNCT06704399Updated Oct 13, 2026

Psychoeducation Based on Acceptance and Commitment Therapy

An interventional study of Acceptance and Commitment Therapy-Based Psychoeducation and control group in Panic Disorder, sponsored by Muğla Sıtkı Koçman University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Muğla Sıtkı Koçman University · Not applicable, Interventional, and Health services research

Updated Oct 13, 2026Now CompletedFirst site in Turkey (Türkiye)+7 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of this study is to manage individual psychoeducation in acceptance and commitment therapy for problems with panic disorder and to evaluate the effect of this program on rumination and self-resilience.

Read the detailed description

Panic disorder; palpitations, sweating, tachycardia, fear of death, depersonalization, derealization, fear of going crazy, etc. It is a psychiatric disorder with symptoms. The most commonly used psychotherapy method for panic disorder patients is cognitive behavioral therapies. Acceptance and Commitment Therapy is a psychotherapy method originating from cognitive behavioral therapy. Acceptance and Commitment Therapy helps individuals act in the direction of their values by allowing them to contact their painful experiences rather than trying to escape or try to get rid of their difficult experiences, thoughts, and feelings. Acceptance and Commitment Therapy supports psychological well-being by providing psychological flexibility in the person. Rumination is mental rumination, which is used to keep thoughts spinning in the mind repetitively after an event.Self-compassion is a concept used to mean understanding oneself despite one's mistakes. This study aims to create psychoeducation based on acceptance and commitment therapy for patients with panic disorder and to evaluate the effect of this program on rumination and self-compassion. Psychoeducation, an evidence-based practice, is very important for the nursing profession. Although nurses have a significant impact on psychoeducational practices, this role is ignored and not implemented adequately. In addition, since there is no research examining the concepts of rumination and self-compassion together in people with panic disorder, it is thought that our study will be useful in new research.

02

Conditions studied

  • Panic Disorder

Browse trials for

Keywords

  • rumination
  • self-compassion
03

In context

Panic Disorder

270 studies on the registry are indexed under Panic Disorder; 37 are open to participants now.

This study's enrollment of 50 is below the median of 77 across 215 interventional studies indexed under Panic Disorder.

Browse Panic Disorder studies →

Lead sponsor

Muğla Sıtkı Koçman University is the lead sponsor of 114 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with Panic Disorder followed in Muğla Training and
  • Research Hospital Psychiatry Polyclinics,
  • Those between the ages of 18-65 who agree to participate in the research,
  • Those who were in a euthymic mood during the interview, according to physician control,
  • Those who speak Turkish,
  • Those who are literate,
  • Those who have a computer and internet access for the program to be conducted online if deemed necessary during the research process,
  • Not having undergone such training within the last year is within the scope of the inclusion criteria.

Exclusion criteria

Exclusion Criteria:

  • Having a diagnosis of a psychiatric disease in addition to panic disorder,
  • Having an attack period during the training period,
  • Individuals with cognitive (diagnosed by a physician) and physical disability (hearing, speaking, etc.) are included in the exclusion criteria from the study.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    psycoeducation

    Psychoeducation based on acceptance and commitment therapy will be applied to the experimental group of 25 people. Pre-test, post-test and follow-up test will be applied.

    Other: Acceptance and Commitment Therapy-Based Psychoeducation

  • Active comparator
    control

    No intervention will be applied to the control group of 25 people. Pre-test, post-test and follow-up test will be applied.

Interventions

  • OtherAcceptance and Commitment Therapy-Based Psychoeducation

    Psychoeducation based on acceptance and commitment therapy will be applied to the experimental group.

  • Othercontrol group

    No intervention will be applied to the control group.

06

What researchers measure

Primary outcomes

  1. Ruminative Thought Style Questionnaire

    The scale is a 7-point Likert type consisting of 20 items. 7 = Very good and 1 = Not at all, and participants are asked to score each item according to how much it reflects themselves. The internal consistency coefficient of the scale, Cronbach's alpha value, was found to be .907. In the item analysis, the item total score correlation was calculated and the total correlations of the items were found to be between 0.474 and 0.699.

    Time frame: 7 week

Secondary outcomes

  1. Self Compassion Scale

    The original Self-Compassion Scale consists of 6 subscales containing 26 items. The scale is a 5-point Likert type and those who answer "almost never = 1 and almost always = 5" are asked to rate how often they move. The Turkish form of the self-compassion scale, unlike the original, consists of 24 items because the scale shows a unidimensional structure and at the same time, 2 items with item-total correlations below 30 were removed from the scale. The internal consistency coefficient of the scale was calculated as .89 and the test-retest correlation was calculated as .83.

    Time frame: 7 week

07

Study locations

1 site
  • Mugla Sıtkı Koçman University
    Muğla, Mentese 48000, Turkey (Türkiye)
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2026 to primary completion in Aug 2026, 2 months.

Of 87 non-industry interventional studies with no phase under Panic Disorder, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's 2 months is below that.

Counting every sponsor, half of 87 studies reached it within 38 months; a quarter within 21 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Sep 2025 → Jun 2026, primary completion Sep 2026 → Aug 2026 and completion Jun 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Nov 26, 2024
StartActual
Jun 21, 2026was Sep 2025
Primary completionActual
Aug 26, 2026was Sep 2026
CompletionActual
Sep 26, 2026was Jun 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 13, 2026
Sites
1 site added, 1 site removed — first site in Turkey (Türkiye); no longer in Turkey
Show site
  • Mugla Sıtkı Koçman University · Muğla, Turkey (Türkiye)
Show 1 removed
  • Mugla Sıtkı Koçman University · Mugla, Turkey
Oct 13, 2026
Start date
Sep 30, 2025→Jun 21, 2026 (actual)
Oct 13, 2026
Primary completion
Sep 30, 2026→Aug 26, 2026 (actual)
Oct 13, 2026
Study completion
Jun 30, 2027→Sep 26, 2026 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Completed
    1 site added, 1 site removed — first site in Turkey (Türkiye); no longer in Turkey
    Show site
    • Mugla Sıtkı Koçman University · Muğla, Turkey (Türkiye)
    Show 1 removed
    • Mugla Sıtkı Koçman University · Mugla, Turkey
    Start date Sep 30, 2025→Jun 21, 2026 (now actual)
    Primary completion Sep 30, 2026→Aug 26, 2026 (now actual)
    Study completion Jun 30, 2027→Sep 26, 2026 (now actual)
    + 4 other changes: verification date, oversight details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06704399
Responsible party
Fatmanur ÖZCAN MİRCALI (Principal investigator, PhD student, Muğla Sıtkı Koçman University) — Principal investigator
First posted
Nov 26, 2024
Start date
Jun 21, 2026
Primary completion
Aug 26, 2026
Completion
Sep 26, 2026
Last update
Oct 13, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion